Feb. 23 at 3:54 PM
$CRMD "Many ESRD patients begin dialysis with a central venous catheter, which while necessary, poses a high infection risk. Although our long-term goal
is to transition patients to permanent access bloodstream infection prevention remains even more critical during this period. Antimicrobial
interventions reduce infection rates by 70% compared to conventional care. In August, we launched a program to further increase antimicrobial
catheter treatments to eligible patients. Adoption to date has been strong, with 84% of eligible capita patients now receiving bloodstream infection
protection, and we are on track to achieve even greater utilization". The last earning call (q3) transcription; page 3
$FMS
